Abbott dorsal column stimulator update#
Abbott dorsal column stimulator trial#

ON average, people who received SCS therapy experienced a 69.7% reduction in pain. In the study, 91.4% of people who received SCS therapy obtained significant pain relief or significantly improved function. Comprised of 270 individuals who suffered an average of 12.8 years with pain, 72.6% of those in the SCS study arm and 85.2% of those implanted achieved significant back pain reduction compared with only 7.1% of individuals in the conventional medical management (CMM) arm.Īll of Abbott’s SCS therapies in the US feature the company’s proprietary, low-energy BurstDR waveform, which had efficacy further supported by DISTINCT.

Abbott dorsal column stimulator trial#

The approval was based on the DISTINCT study (NCT0447987), the largest randomized controlled trial for SCS in people with chronic back pain for which surgery is not an option. The new indication spans across the entire SCS program, which includes the recharge-free Proclaim SCS family and the rechargeable Eterna SCS platform. It allows clinicians to get to the source of a particular issue in less time and without fear of compromising safety or creating complications, ' said Timothy Deer, MD, president and chief executive officer at The Spine and Nerve Centers of the Virginias, serving West Virginia.According to an announcement, the FDA has approved Abbott’s spinal cord stimulation (SCS) devices for the treatment of chronic back pain in individuals who have not or are not eligible to receive back surgery. 'Now more clinicians can utilize MRIs to improve quality of care among a patient population with complex needs.

Abbott dorsal column stimulator update#

The label update will also benefit existing patients implanted with Proclaim XR SCS Systems with Octrode leads improving their access to MRI imaging. In general, the FDA requires radiologists to pause MRIs for anywhere from 30 to 60 minutes between scan cycles for patients with implants.

If a scan exceeds a certain amount of time without a break, radiofrequency energy used during the scans has the potential to heat up the implanted device, which can damage the surrounding tissue. Under the expanded labeling, patients with a Proclaim XR SCS device only need to wait 30 minutes between scan cycles of 30 minutes, allowing them to safely receive an MRI scan in a fraction of the time. By improving the quality of imaging, as well as the experience for both the patient and radiologist, I can now enable more of my existing and new patients to benefit from MRI scans improving their care,' said Steven Falowski, MD, neurosurgeon at Neurosurgical Associates of Lancaster in Pennsylvania. 'The expanded labeling and reduced scan time address two major issues we face with these implantable devices. Radiofrequency energy no longer needs to be limited with Proclaim SCS and Octrode devices as long as the MRI is in the normal operating mode. With the new labeling, Octrode lead tips can be placed anywhere they are needed along the spine and still be considered MR Conditional, which means a patient can undergo MRI scans within the approved outlined conditions. The Proclaim XR SCS System is an implantable spinal cord stimulation device designed to allow patients to attain relief from chronic pain of the trunk and limbs. 'We made it our mission to secure expanded MRI labeling for our spinal cord stimulation devices – both those that were already implanted and those still to be implanted – for the sake of the patients and their doctors.' Burton, MD, medical director of Abbott's neuromodulation business. They are particularly important for patients who have certain comorbidities, such as cancer or multiple sclerosis,' said Allen W.

'MRIs have increasingly become an important tool helping doctors diagnose an illness or injury. Under the expanded MRI labeling, patients with a Proclaim XR SCS device can benefit from higher quality images with faster MRI scan times. The new labeling lifts MRI restrictions for lead tip location and the amount of radiofrequency power that can be used as part of the normal operating mode of an MRI scan, covering the majority of Proclaim XR patients. The US Food and Drug Administration (FDA) has approved new expanded MRI compatibility for Abbott’s Proclaim XR Spinal Cord Stimulation (SCS) System with Octrode leads.